Compared to DTC, PDTC and ATC have a higher tumor mutation burden and a higher frequency of mutations involving TERT promoter; tumor-suppressor genes, including TP53; PI3K/AKT/mTOR pathway genes; cell-cycle genes, including CDKN2A, CDKN2B, and CCNE1; and genes associated with SWI/SNF nucleosome remodeling and histone modification (Figure 1) [14,15]. This evidence concerns the gene MTOR and neoplasm.